Efficacy and safety in SGLT2 inhibitor for non-diabetes complicated by non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. - SGLT2 inhibitor for non-diabetes complicated by NAFLD/NASH.

Kobe university school of medicine, Diabetes and Endocrinoplogy0 个研究点目标入组 30 人开始时间: 2018年1月29日最近更新: 2023年10月17日

试验速览

暂无简介。

•(1)Choronic hepatitis such as liver cirrhosis, viral hepatitis, alcoholic hepatitis (2)Known or suspected abuse of alcohol (3)Treatment with steroid (4)Patients with severe vascular disease such as stroke, myocardial infarction within the past 6 months (5)Impaired liver function, defined as alanine aminotransferase >4 times upper limit of normal, or Child-pugh C cirrhosis (6)Impaired renal function defined as eGFR <45ml/min (7)Treatment with SGLT2 inhibitor or pioglitazone (8)Pregnancy or breast feeding (9)Cancer and other severe disease (10)Patients with mental illness or drug addicts (11)Patients who are difficult to perform MRI examination such as implantable defibrillators and internal metals (12)Others judged unsuitable by researchers

发起方

Kobe university school of medicine, Diabetes and Endocrinoplogy